Atlas Trials

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Clinical trial NCT05281406 · RECRUITING

Trial details

NCT number
NCT05281406
Sponsor
Goethe University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC Stage IIIBNSCLC Stage IV
Start date
2021-11-12
Primary completion
2025-11-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.